New D-BSSE startup revolutionises treatment of metabolic diseases
CreARTO Bioscience, a recently founded ETH startup originating from the Biotechnology lab of Martin Fussenegger, offers a synthetic biology-based platform technology that reprograms stem cells for the treatment of metabolic diseases. The first product will target type 1 diabetes.
After years of research in the Fussenegger lab, the startup CreARTO Bioscience AG was founded with six co-founders from different fields of expertise. The team consists of experienced and leading biologists, physicians and economists. Two co-founders from D-BSSE are Prof. Martin Fussenegger and Dr. Ana Palma Texeira (CSO).
The new D-BSSE startup will fundamentally change the treatment paradigm for insulin-dependent patients with a synthetic biology-based platform technology. With the unique genetic software it is possible to reprogram stem cells. This will allow CreARTO to treat metabolic diseases in a groundbreaking way using modified cells. This disruptive technology creates the opportunity to change the life of millions of patients with type 1 diabetes.
The first lead indication is type 1 diabetes. The therapeutic agent consists of islet cells differentiated in vitro from human stem cells, which constitute an unlimited cell source for transplantation into patients who lost their insulin-producing beta cells. The therapeutic cells will be encapsulated in immunoprotected capsules to alleviate safety concerns while enabling control of glucose homeostasis.
Find information on the Biotechnology lab led by Martin Fussenegger.
Learn about all D-BSSE spinoff companies.